Pharmacists in Halfmoon, New York


13 Pharmacists found in Halfmoon
female pharmacist

Amelia Anne Ekert


Pharmacist
121 Old Route 146, Halfmoon, NY 12065
518-371-5842    

male pharmacist

Brian J Mack, RPH


Pharmacist
1549 Route 9, Walmart Pharmacy, Halfmoon, NY 12065
518-373-5732     518-373-5753

male pharmacist

Cody Michael Fournier, PHARMD


Pharmacist
121 Old Route 146, Halfmoon, NY 12065
518-371-5842     518-371-5931



female pharmacist

Dr. Hayley Fraser, PHARMD


Pharmacist
1009 Schooner Ct, Halfmoon, NY 12065
315-560-9108    

female pharmacist

Holly Anne Fluri


Pharmacist
1701 Route 9, Halfmoon, NY 12065
518-371-5303    

female pharmacist

Hui Cheng, PHARM D


Pharmacist
1483 Route 9, Halfmoon, NY 12065
518-371-1513    

female pharmacist

Megan Ashley Gerken, PHARMD, RPH


Pharmacist
121 Old Route 146, Halfmoon, NY 12065
518-371-5842    

male pharmacist

Michael David Masterson, PHARMACIST


Pharmacist - Oncology
3 Crossing Blvd, Halfmoon, NY 12065
518-831-4434     518-831-4562

male pharmacist

Mr. Michael David Sautter, PHARMD


Pharmacist
1549 Route 9, Walmart Pharmacy, Halfmoon, NY 12065
518-373-5732    

female pharmacist

Nicole A Valente


Pharmacist
1483 Route 9, Halfmoon, NY 12065
518-371-1513    

female pharmacist

Dr. Patricia Rachel Drake, PHARMD


Pharmacist
1476 Route 9, Halfmoon, NY 12065
518-373-4950    

female pharmacist

Tanya Ahuja, RPH


Pharmacist
20 Shelbourne Dr, Halfmoon, NY 12065
518-330-1119    

male pharmacist

Dr. Thomas Henry Colligan Iv, PHARMD, RPH


Pharmacist
1549 Route 9, Halfmoon, NY 12065
518-373-5732     518-373-5753


Type of Pharmacists:
Psychiatric Pharmacist: A licensed pharmacist who has demonstrated specialized knowledge and skill in optimizing care of patients with psychiatric illness by assessing and monitoring patients, recognizing drug-induced problems, and recommending appropriate treatment plans.
Oncology Pharmacist: A licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases.